Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Proffered paper session - Genitourinary tumours, non prostate

3687 - Nivolumab (N) Alone or in Combination With Ipilimumab (I) in Patients (pts) With Platinum-Pretreated Metastatic Urothelial Carcinoma (mUC), Including the Nivolumab 1 mg/kg + Ipilimumab 3 mg/kg Expansion From CheckMate 032


20 Oct 2018


Proffered paper session - Genitourinary tumours, non prostate



Tumour Site

Urothelial Cancer


Jonathan Rosenberg


J.E. Rosenberg1, P. Sharma2, F.G.M. de Braud3, U. Basso4, E. Calvo5, P. Bono6, M. Morse7, P.A. Ascierto8, J.A. Lopez-Martin9, P. Brossart10, K.S. Rohrberg11, N. Reguart12, W.H. Lin13, S. Meadows-Shropshire14, A. Saci15, M. Callahan1, A.O. Siefker-Radtke16

Author affiliations

  • 1 Medicine, Memorial Sloan-Kettering Cancer Center, 10065 - New York/US
  • 2 Genitourinary Medical Oncology, MD Anderson Cancer Center, 77030-4095 - Houston/US
  • 3 Medical Oncology & Haematology, Istituto Nazionale dei Tumori, 20133 - Milan/IT
  • 4 Medical Oncology, Istituto Oncologico Veneto IOV IRCCS, 35128 - Padua/IT
  • 5 Start Madrid- Ciocc, Centro Integral Oncológico Clara Campal, 28050 - Madrid/ES
  • 6 Comprehensive Cancer Center, Helsinki University Hospital, 00029 - Helsinki/FI
  • 7 Medical Oncology, Duke University Medical Center, 27710 - Durham/US
  • 8 Melanoma, Cancer Immunotherapy And Development Therapeutics Unit, Istituto Nazionale Tumori Fondazione G. Pascale, 80131 - Naples/IT
  • 9 Medical Oncology, University Hospital 12 De Octubre, 28041 - Madrid/ES
  • 10 Hematology-oncology, University Hospital of Bonn, 53105 - Bonn/DE
  • 11 Oncology, Rigshospitalet, University Hospital of Copenhagen, 2100 - Copenhagen/DK
  • 12 Oncology, Hospital Clinic of Barcelona, 08036 - Barcelona/ES
  • 13 Bms Clinical, Bristol Myers Squibb, 08536 - Princeton/US
  • 14 Global Biometric Sciences, Bristol-Myers Squibb, 08536 - Princeton/US
  • 15 Clinical Biomarkers, Bristol-Myers Squibb, 08648 - Princeton/US
  • 16 Genitourinary Medical Oncology, MD Anderson Cancer Center, 77030-3721 - Houston/US


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3687


CheckMate 032 is a multi-cohort study which included N monotherapy (3 mg/kg; N3) and 2 different regimens of N+I (N 3mg/kg + I 1mg/kg [N3I1] or N 1 mg/kg + I 3 mg/kg [N1I3]) treatment in pts with platinum-pretreated mUC. We previously reported an objective response rate (ORR) of 26% with both N3 (n=78) and N3I1 (n=104), and a preliminary ORR of 38% with N1I3 (n=26). Here we report on the expanded N1I3 cohort and extended follow-up data.


This multicenter, open-label study enrolled pts with previously treated locally advanced or mUC, RECIST v1.1 measurable disease, and ECOG performance status ≤1. Pts received either N3 Q2W, N3I1 Q3W for 4 cycles followed by N3 Q2W, or N1I3 Q3W for 4 cycles followed by N3 Q2W until disease progression or unacceptable toxicity. Pts in the N3 cohort could cross over to N3I1 upon progression. The primary endpoint was investigator-assessed ORR per RECIST v1.1 with duration of response (DOR). Secondary endpoints included investigator-assessed progression-free survival (PFS), overall survival (OS), and safety.


With a minimum follow-up of 37.7 mo (N3; n=78), 38.8 mo (N3I1; n=104), and 7.9 mo (N1I3; n=92), ORR was 26%, 27%, and 38%, respectively (Table). Most pts were heavily pretreated. The ORR with N1I3 was highest in pts with PD-L1 ≥1% (58%; Table). Median PFS and OS were numerically longer with N1I3 (Table). Grade 3 or 4 treatment-related adverse events (TRAEs) occurred in 21 (27%), 32 (31%), and 36 (39%) pts with N3, N3I1, and N1I3, respectively. One pt each in the N3 and N3I1 arms had a grade 5 TRAE (pneumonitis).







Minimum follow-up, mo




ORR (95% CI), %

26 (16–37)

27 (19–37)

38 (28–49)

PD-L1 ≥1%

27 (12–48)

35 (19–55)

58 (39–76)

PD-L1 <1%

26 (14–41)

25 (14–38)

24 (12–40)

Median DOR (95% CI), mo

30.5 (8.3–NE)

22.3 (12.8–NE)

22.9 (9.8–NE)

Median PFS (95% CI), mo

2.8 (1.5–5.3)

2.6 (1.4–3.9)

4.9 (2.7–6.6)

Median OS (95% CI), mo

9.9 (7.3–21.1)

7.4 (5.6–11.0)

15.3 (10.1–27.6)

NE, not estimable


The combination of N1I3 demonstrated higher ORR and longer PFS and OS than previous reports of PD-1/PD-L1 monotherapies in this PD-L1 unselected pt population with a manageable safety profile. These results support the ongoing phase 3 trial of N1I3 vs chemotherapy in previously untreated mUC (CheckMate 901; NCT03036098).

Clinical trial identification


Editorial Acknowledgement

Professional medical writing and editorial assistance was provided by Nicolette Belletier and Lawrence Hargett of PPSI (a PAREXEL company), funded by Bristol-Myers Squibb

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.